<DOC>
	<DOCNO>NCT02856464</DOCNO>
	<brief_summary>The trial conduct multicentre open label , randomise prospective phase II clinical trial patient high risk myeloid malignancy . The primary objective evaluate whether prophylactic donor lymphocyte infusion ( DLI ) deliver part plan schedule improve disease free survival patient myeloid malignancy .</brief_summary>
	<brief_title>Prophylactic DLI Prevention Relapse Post HSCT Patients With High Risk Myeloid Malignancy</brief_title>
	<detailed_description />
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<criteria>Patient Inclusion Criteria 1 . Haematological cancer one follow 1 . Acute Myeloid Leukaemia ( AML ) Intermediate High risk CR1 2 . AML favourable risk CR2 3 . Patients AML MDS residual cytogenetic molecular disease preHSCT 4 . CMML 5 . Myelodysplastic Syndrome ( MDS ) define IPSS category int1 high &lt; 5 % blast time randomisation follow cytoreduction necessary 6 . Secondary MDS AML ; define arise antecedent haematological disease secondary prior chemotherapy . 2 . Patients sibling 9/10 10/10 HLA match unrelated donor 3 . Patients receive alemtuzumab base reduced intensity condition HSCT 4 . Age &gt; /=18 year 5 . Able comprehend give inform consent Patient Exclusion Criteria 1 . Patients &gt; 5 % blast time HSCT 2 . Patients eligible myeloablative ( Bu/Cy Cy/TBI ) HSCT protocols 3 . Patients myelofibrosis 4 . Patients hypersensitivity alemtuzumab , melphalan , fludarabine busulphan 5 . ECOG performance status &gt; 2 6 . Patients pregnant lactate</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>